# Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

> **NCT06505018** · NA · RECRUITING · sponsor: **UNICANCER** · enrollment: 472 (estimated)

## Conditions studied

- Metastatic Triple-Negative Breast Carcinoma

## Interventions

- **DEVICE:** Cureety techcare

## Key facts

- **NCT ID:** NCT06505018
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-25
- **Primary completion:** 2026-09-01
- **Final completion:** 2028-09-02
- **Target enrollment:** 472 (ESTIMATED)
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06505018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06505018, "Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06505018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*